13:39:17 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-02-27 Bokslutskommuniké 2024
2024-11-28 Kvartalsrapport 2024-Q3
2024-08-22 Kvartalsrapport 2024-Q2
2024-05-16 Kvartalsrapport 2024-Q1
2024-05-13 Ordinarie utdelning DEAR 0.00 SEK
2024-05-08 Årsstämma 2024
2024-02-22 Bokslutskommuniké 2023
2024-01-31 Extra Bolagsstämma 2024
2023-11-30 Kvartalsrapport 2023-Q3
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-04 Kvartalsrapport 2023-Q1
2023-04-13 Ordinarie utdelning DEAR 0.00 SEK
2023-04-12 Årsstämma 2023
2023-02-23 Bokslutskommuniké 2022
2022-11-17 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-19 Kvartalsrapport 2022-Q1
2022-04-08 Ordinarie utdelning DEAR 0.00 SEK
2022-04-07 Årsstämma 2022

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Duearity är verksamt inom medicinteknik. Bolaget är specialiserat inom utveckling och produktion av tekniska lösningar för behandling och lindring av tinnitus. Produktportföljen inkluderar exempelvis bolagets egenutvecklade produkter Tinearity och Duearity. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster. Verksamheten bedrivs inom Sverige.
2023-08-25 10:29:00

Duearity AB's subsidiary in the US, Duearity Americas Inc, has signed agreements with the first five clinics. The clinics intend to purchase Tinearity G1 for their tinnitus patients. A reasonable assessment is that approximately ten clinics in the US have entered into agreements with the company during the third quarter of 2023.

Duearity Americas Inc has signed evaluation agreements with five clinics in the United States that intend to purchase Tinearity G1 for their tinnitus patients. The agreements mean that Duearity Americas Inc can carry out the first sales during the third quarter. Duearity received market approval on June 30 this year and sales activities started immediately after that. The assessment is that Duearity Americas Inc has entered into agreements with approximately ten clinics before the end of the third quarter.

- The interest among audiology clinics in the US has so far exceeded expectations and it is clear that Tinearity G1 fills a gap in the market. We will sell the device to clinics in a few selected states and aim to enter into distribution agreements in states that we do not intend to process ourselves. Another important channel is Veteran Affairs, which could become very profitable for the company, says David Johansson, Managing Director of Duearity Americas Inc.